Cana Laboratories Secures Major Deal with Viofar for Rosartia Medicine

Cosmos Health's Cana Laboratories has entered into a five-year contract manufacturing deal with Viofar to supply an additional 2.5 million units of the Rosartia cardiovascular medicine.

Under this agreement, Cana will produce 500,000 units annually across four dosages: 5mg, 10mg, 20mg, and 40mg.

The deal increases Cana's cumulative contract manufacturing orderbook to over 27.5 million units and provides greater visibility into future production volumes and related cash flows.